Akums Drugs and Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹4,359cr+5.8% on FY25
EBITDA: ₹522cr+12.4% on FY25
Net profit: ₹256cr−25.4% on FY25
EPS: ₹16.67−26.2% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	4,502	4,359	4,118
	132	129	52.1
	4,634	4,488	4,170
	2,433	2,299	2,254
	206	201	181
	−62.3	13.8	−1.6
	779	754	716
	95.7	94.1	34.6
	159	155	153
	578	570	504
	4,188	4,086	3,842
	568	522	464
	409	367	311
Profit
	446	402	329
	−20.0	−20.0	16.7
	426	382	345
	92.5	89.8	79.7
	40.5	35.9	−78.3
	133	126	1.5
	293	256	344
	293	256	344
	2.3	0.9	−1.1
	295	257	343
	292	255	338
	1.0	1.2	5.6
Per share
	₹19.05	₹16.67	₹22.60
	₹19.05	₹16.67	₹22.60
Other comprehensive income — detail
	2.3	0.9	−1.1
	—	1.3	−1.4
	7.1	0.4	−0.3
	—	−0.0	—
	−1.1	0.0	0.0
	294	256	337
	0.9	1.2	5.6
Per share — as-filed variants
	₹19.05	₹16.67	₹22.60
	₹19.05	₹16.67	₹22.60
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,925	1,845	1,685
	42.8%	42.3%	40.9%
Adjusted (ex-exceptional items) — derived
	446	402	329
	−20.0	−20.0	16.7
	306	270	327
	₹19.95	₹17.54	₹21.51

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersALIVUS AGARWALEYE ADVENZYMES APLLTD AARTIPHARM AARTIDRUGS CORONA HCGMcap ₹11,346 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	4,118.2	4,359.0	4,501.6
Other Income	52.1	128.7	132.4
Total Income	4,170.3	4,487.7	4,634.0
Expenses
+ Cost of Materials Consumed	2,253.6	2,298.7	2,432.9
+ Purchases of Stock-in-Trade	181.5	201.0	206.4
+ Changes in Inventories	-1.6	13.8	-62.3
+ Employee Benefit Expense	715.8	753.8	779.1
+ Finance Costs	34.6	94.1	95.7
+ Depreciation & Amortisation	153.4	154.6	158.7
+ Other Expenses	504.4	569.7	577.7
Total Expenses	3,841.7	4,085.6	4,188.3
EBITDA	464.5	522.0	567.7
EBIT	311.0	367.5	409.0
Profit
PBT before Exceptional Items	328.6	402.1	445.7
+ Exceptional Items	16.7	-20.0	-20.0
Pretax Income	345.3	382.1	425.7
+ Current Tax	79.7	89.8	92.5
+ Deferred Tax	-78.3	35.9	40.5
Tax Expense	1.5	125.7	133.0
Net Income	343.8	256.4	292.7
+ Net Income — Continuing Ops	343.8	256.4	292.7
+ Other Comprehensive Income	-1.1	0.9	2.3
Total Comprehensive Income	342.7	257.3	295.0
Net Income to Common	338.2	255.2	291.7
Minority Interest	5.6	1.2	1.0
Per Share
Basic EPS	22.60	16.67	19.05
Diluted EPS	22.60	16.67	19.05
Other Comprehensive Income — detail
+ Other Comprehensive Income	-1.1	0.9	2.3
+ Items NOT to be Reclassified to P&L	-1.4	1.3	—
+ Tax on Items NOT to be Reclassified	-0.3	0.4	7.1
+ Items to be Reclassified to P&L	—	-0.0	—
+ Tax on Items to be Reclassified	0.0	0.0	-1.1
Comprehensive Income — Owners of Parent	337.1	256.1	294.0
Comprehensive Income — Non-controlling Interests	5.6	1.2	0.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	22.60	16.67	19.05
Diluted EPS — Continuing Operations	22.60	16.67	19.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,684.7	1,845.5	1,924.6
Gross Margin %	40.91	42.34	42.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	328.6	402.1	445.7
− Exceptional Items (reconciliation)	16.7	-20.0	-20.0
Net Income Adj (tax-effected)	327.2	269.8	306.5
EPS Adj	21.51	17.54	19.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	2.00	2.00
Paid Up Equity Capital	30.6	30.6	30.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.